Compositions and methods related to Rhamnus prinoides (gesho) extract for the inhibition of polymicrobial biofilm formation

Patent metadata

Field	Value
Publication number	US-12403169-B2
Application number	US-202318345643-A
Country	US
Kind code	B2
Filing date	Jun 30, 2023
Priority date	May 7, 2018
Publication date	Sep 2, 2025
Grant date	Sep 2, 2025

Abstract

Disclosed are compositions comprising Rhamnus prinoides (GESHO) extract or fragments thereof and methods of using Gesho extract for the inhibition of biofilm formation.

First claim

What is claimed is:

1. A method of inhibiting biofilm formation on a surface comprising contacting a surface susceptible to biofilm formation with a composition consisting of 4-hydroxy-4-methylpentanone (HMP) and a pharmaceutically acceptable carrier or a composition consisting of a pharmaceutically acceptable carrier, HMP, and at least one small molecule selected from the group consisting of: an extract of Rhamnus prinoides (gesho), 4-ethoxy benzoic acid (4EB), ethyl 4-ethoxybenzoate (EEB), methyl gallate, methyl paraben, adipic acid, phytol, or phytol acetate; and wherein the biofilm is not caused by Staphylococcus aureus.

2. The method of claim 1 , wherein the surface is in a subject and the method comprises administering to the subject a composition comprising a therapeutically effective amount of a composition comprising 4-hydroxy-4-methylpentanone (HMP).

3. The method of claim 1 , wherein the surface is selected from the group consisting of: a medical instrument, artificial joint, artificial heart valve, venous catheter, urinary catheter, ventilator, food handling, water handling, pipes, tooth, oral cavity, denture, body, wound, rash, abrasion, cut, surgical incision, implant, and nose.

4. The method of claim 1 , wherein the biofilm is caused by a prokaryotic organism.

5. The method of claim 4 , wherein the prokaryotic organism is a Gram positive organism.

6. The method of claim 5 , wherein the Gram positive organism comprises Streptococcus mutans , or Bacillus subtilis.

7. The method of claim 4 , wherein the prokaryotic organism is a Gram negative organism.

8. The method of claim 7 , wherein the Gram negative organism comprises Pseudomonas aeruginosa.

9. The method of claim 8 , which further comprises contacting the surface with a composition comprising vancomycin.

10. The method of claim 1 , wherein the biofilm is caused by a eukaryotic organism.

11. The method of claim 10 , wherein the eukaryotic organism comprises Candida albicans.

12. The method of claim 1 , wherein the biofilm is caused by prokaryotic organism and a eukaryotic organism.

13. The method of claim 1 , wherein the method inhibits one or more virulence factors.

14. A method of enhancing the sensitivity of a biofilm to an antibiotic comprising contacting the biofilm with a composition consisting of 4-hydroxy-4-methylpentanone (HMP) and a pharmaceutically acceptable carrier.

15. A method of claim 14 , further comprising contacting the biofilm with a composition comprising an antibiotic.

16. A composition useful for biofilm inhibition, consisting of 4-hydroxy-4-methylpentanone (HMP) and a pharmaceutically acceptable carrier.

17. A composition of claim 16 , which further comprises an antibiotic.

18. A composition of claim 17 , wherein the antibiotic is vancomycin.

19. A composition of claim 16 , wherein the composition is selected from the group consisting of: surface cleaner, disinfectant, sanitizer, mouth rinse paint, caulk, adhesive, shampoo, body wash, medicated sponges, scaffolds, stents, matrixes, grafts, bandages, adhesive bandages, wound dressings, surgical drapes, sutures, staples, surgical adhesives, salves, creams, wound adhesives, and pharmaceutical composition.

20. The composition of claim 16 , further comprising an isolated small molecule derivative comprising at least one composition selected from the group consisting of: an extract of Rhamnus prinoides (gesho), 4-ethoxy benzoic acid (4EB), ethyl 4-ethoxybenzoate (EEB), methyl gallate, methyl paraben, adipic acid, phytol, or phytol acetate.

21. A method of inhibiting biofilm formation in a subject comprising administering to the subject the composition of claim 16 and inhibiting biofilm formation in the subject.

22. The method of claim 21 , wherein the subject has at least one biofilm-associated disease selected from the group consisting of: tooth decay, cystic fibrosis, pneumonia, device associated infection, and chronic wound infections.

23. A method of inhibiting biofilm formation on a surface comprising contacting a surface susceptible to biofilm formation with a composition consisting of 4-hydroxy-4-methylpentanone (HMP) or a composition comprising HMP and at least one small molecule selected from the group consisting of: an extract of Rhamnus prinoides (gesho), 4-ethoxy benzoic acid (4EB), ethyl 4-ethoxybenzoate (EEB), methyl gallate, methyl paraben, adipic acid, phytol, or phytol acetate; wherein the biofilm is not caused by Staphylococcus aureus ; and wherein the composition does not further include one or more active ingredients such as antimicrobial agents, anti-inflammatory agents, or anesthetics.

Assignees

• Univ Georgia State Res Found

Inventors

• Campbell Mariya
• Gilbert Eric

Classifications

• A61L2103/15

  Laboratory, medical or dentistry appliances, e.g. catheters or sharps · CPC title

• A61L2/18

  Liquid substances · CPC title

• A61K31/192

  having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid  {(cannabinoids A61K31/658)} · CPC title

• C11D2111/14

  Hard surfaces · CPC title

• C11D3/48

  Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions · CPC title